Tage-Jensen U, Schlichting P, Aldershvile J, Andersen P, Dietrichson O, Hardt F, Mathiesen L R, Nielsen J O
Liver. 1982 Jun;2(2):95-103. doi: 10.1111/j.1600-0676.1982.tb00184.x.
One hundred and forty-eight patients with non-alcoholic cirrhosis or chronic aggressive hepatitis entered a prospective, unblinded, randomized trial on the effect of azathioprine versus prednisone. For all 148 patients, there were no differences in survival related to the two drugs. In 99 patients the disease was classified as autoimmune, in 23 as posthepatitic, and in 26 as cryptogenic. No significant differences were seen in survival between these three groups of patients and no differences in survival related to the two drugs were registered within any of the groups. The autoimmune group included the patients with the biochemically most active disease, and a statistically significant reduction in activity was obtained with prednisone as well as azathioprine. Most remarkably, the frequencies of the autoantibodies were reduced parallel to the biochemical improvement in these patients. Immunosuppressive treatment was found to be rather ineffective in posthepatic chronic liver disease of type B; however, no signs of activation of the hepatitis B virus were seen.
148例非酒精性肝硬化或慢性侵袭性肝炎患者参与了一项关于硫唑嘌呤与泼尼松疗效对比的前瞻性、非盲法、随机试验。对于所有148例患者而言,两种药物对生存率的影响并无差异。99例患者的疾病被归类为自身免疫性疾病,23例为肝炎后疾病,26例为隐源性疾病。这三组患者的生存率未见显著差异,且在任何一组内,两种药物对生存率的影响也无差异。自身免疫性疾病组包含生化活性最高的疾病患者,使用泼尼松和硫唑嘌呤均可使活性出现统计学上的显著降低。最值得注意的是,这些患者自身抗体的频率随着生化指标的改善而平行降低。免疫抑制治疗在B型肝炎后慢性肝病中效果不佳;然而,未观察到乙肝病毒激活的迹象。